Great Point Partners LLC Purchases 203,120 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Great Point Partners LLC raised its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 25.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,000,000 shares of the company’s stock after buying an additional 203,120 shares during the period. Olema Pharmaceuticals comprises 3.5% of Great Point Partners LLC’s portfolio, making the stock its 13th biggest position. Great Point Partners LLC’s holdings in Olema Pharmaceuticals were worth $11,940,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of OLMA. Point72 Asset Management L.P. bought a new stake in Olema Pharmaceuticals during the 2nd quarter worth approximately $34,753,000. Candriam S.C.A. boosted its stake in Olema Pharmaceuticals by 199.9% in the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock worth $11,454,000 after purchasing an additional 705,655 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Olema Pharmaceuticals by 74.5% during the first quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock worth $13,817,000 after purchasing an additional 521,562 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of Olema Pharmaceuticals in the second quarter valued at $2,976,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 168.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after buying an additional 207,565 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on OLMA shares. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $9.72 on Wednesday. Olema Pharmaceuticals, Inc. has a 1 year low of $7.68 and a 1 year high of $16.77. The company’s 50-day moving average is $11.49 and its two-hundred day moving average is $11.90.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.